<DOC>
	<DOCNO>NCT02556021</DOCNO>
	<brief_summary>The purpose study demonstrate superiority efficacy CJ-12420 , daily ( QD ) , compare placebo patient non-erosive reflux disease Week 4</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CJ-12420 Patients With Non Erosive Reflux Disease</brief_title>
	<detailed_description>This double blind , randomize , placebo-controlled , phase 3 study . Subjects randomly assign one three treatment group ( CJ-12420 50 mg 100 mg placebo ) . All subject ask take two tablet time day throughout study , also subject ask record daily symptom subject diary daily basis .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>1 . Subjects age 20 75 year 2 . Subjects experience minimum threemonth history main symptom ( heartburn regurgitation ) 3 . Subjects normal esophagus confirm endoscopy within 14 day prior randomization 4 . Subjects able understand follow instruction willing participate throughout entire study 5 . Subjects voluntarily sign write informed consent form 6 . Subjects agree use medically acceptable contraceptive period study 7 . Subjects experience heartburn regurgitation within 7 day randomization . Entry study also require patient experience least mild upper gastrointestinal symptom least 2 days/week least moderate upper gastrointestinal symptom least 1 day/week 1 . Subjects undergo EGD 2 . Subjects esophageal stenosis , ulcer stenosis , gastroesophageal varix , Barrett 's esophagus , active gastric ulcer , gastrointestinal bleeding malignant tumor confirm EGD 3 . Subjects erosive esophagitis , acute upper gastrointestinal bleeding , gastric ulcer duodenal ulcer , acute erosive gastritis within 2 month randomization . Subjects gastric duodenal erosion allow include . 4 . Subjects warn symptom malignant gastrointestinal tract odynophagia , severe dysphagia , bleeding , weight loss , anemia , bloody stool 5 . Subjects eosinophilic esophagitis 6 . Subjects diagnose functional dyspepsia , primary esophageal motility disorder , IBS , IBD , etc . suspect IBS last 3 month 7 . Subjects history gastric acid suppression surgery upper gastrointestinal , esophageal surgery 8 . Subjects bipolar disorder , anxiety disorder , panic disorder , somatoform disorder , personality disorder psychiatric disorder . 9 . Subjects take antipsychotic drug , antidepressant antianxiety medication 10 . Subjects continuously administer NSAIDs trial . 11 . Pregnant lactate woman 12 . Subjects history clinically significant hepatic , renal , cardiovascular , respiratory , endocrine CNS system disorder 13 . Subjects history hypersensitivity active ingredient excipients study drug , etc . 14 . Subjects participate clinical trial within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>